Journal profile · Hematology
Leukemia
ISSN 0887-6924 · eISSN 1476-5551 · Springer Nature · ENGLAND · Monthly · Founded 1997
Leukemia: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 8.7; hybrid open access; APC about USD 5,190; median 122 days to acceptance (102 articles, last 24 months); community-reported acceptance: hard; 340 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Leukemia is published by Springer Nature and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research and Chronic Myeloid Leukemia Treatments, together about 36.3% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Ranked in the top quartile of journals worldwide in the fields of oncology and hematology, we publish high quality, peer reviewed original content across all aspects of the research and treatment of leukemia and allied diseases. We provide wide exposure and high visibility for your publication through our nature.com platform. We also offer funder-compliant open access options. Leading voices in the field across the globe form our expert editorial team, providing attractive turnaround times from first decision to publication.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Acute Myeloid Leukemia ResearchMedicine16.9%
- Chronic Lymphocytic Leukemia ResearchMedicine10.3%
- Chronic Myeloid Leukemia TreatmentsMedicine9.2%
- Acute Lymphoblastic Leukemia researchMedicine8.6%
- Lymphoma Diagnosis and TreatmentMedicine7.1%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine5.1%
- Multiple Myeloma Research and TreatmentsMedicine5.1%
- Hematopoietic Stem Cell TransplantationMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
| Minor | Hematology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
CINAHLCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, OCLC
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 8.7LetPub ·
- Impact factor (publisher) 2025
- 8.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 10.7Publisher website ·
- CiteScore 2026-06
- 19.2LetPub ·
- SJR 2026-06
- 3.68LetPub ·
- SNIP 2026-06
- 3.13LetPub ·
- h-index
- 176LetPub ·
- h-index
- 261OpenAlex ·
- i10-index
- 8,685OpenAlex ·
- 2-year mean citedness
- 6.89OpenAlex ·
- Self-citation rate
- 4.5%LetPub ·
- Share of gold OA articles
- 65.87%LetPub ·
Volume
- Articles per year
- 221LetPub ·
- Downloads per year (publisher) 2025
- 5,971,872Publisher website ·
Articles by year OpenAlex count · 11,715 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 295 | 198 | 197 |
| 2025 | 340 | 249 | 2,145 |
| 2024 | 369 | 275 | 4,579 |
| 2023 | 317 | 237 | 5,674 |
| 2022 | 330 | 246 | 17,260 |
| 2021 | 373 | 291 | 14,479 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
122 daysMedian, submission to acceptance · P25–P75 82 days – 172 days
- Acceptance to online
- median 17 days (102 articles)
- Submission to online
- median 142 days
- Sample
- 102 articles with submission and acceptance dates (723 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–6 weeksLetPub ·
- Average acceptance (community reports)
- HardLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 5,190 / EUR 4,190 / GBP 3,690 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1997
- ISSN
- 0887-6924
- Electronic ISSN
- 1476-5551
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Leukemia
What CAS zone is Leukemia in?
In the 2025 upgraded edition of the CAS Journal Ranking, Leukemia is in Zone 1 of Medicine, and in Zone 1 of the minor category Hematology / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Leukemia?
The latest impact factor listed by LetPub is 8.7; CiteScore 19.2, h-index 261.
How long does peer review take at Leukemia?
Based on the dates recorded on 102 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 122 days (interquartile range 82–172 days); authors report an average review time of 3–6 weeks; the community-reported acceptance is “Hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Leukemia?
According to LetPub and DOAJ records, Leukemia is indexed in SCIE and Scopus. The journal's website also lists CINAHL and Current Contents; that list has not been checked against each database.
Is Leukemia open access, and what is the APC?
Leukemia is a hybrid journal. For open-access publication: APC about USD 5,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .